![Immunocytochemistry/Immunofluorescence: nNOS Antibody [NB100-858] - Action potentials were evoked with depolarizing current pulses. (A) Neuron from colonic specimen of non-treated patient fired 1 action potential in response to a depolarizing current. (A') Intracellular injection of carboxyfluorescein during recording confirmed Dogiel type I, uniaxonal morphology. (A](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunocytochemistry-Immunofluorescence-NB100-858-img0005.jpg "Immunocytochemistry/Immunofluorescence: nNOS Antibody [NB100-858] - Action potentials were evoked with depolarizing current pulses. (A) Neuron from colonic specimen of non-treated patient fired 1 action potential in response to a depolarizing current. (A') Intracellular injection of carboxyfluorescein during recording confirmed Dogiel type I, uniaxonal morphology. (A")
| Reactivity | Hu, Mu, Rt, Gp, Bv, CaSpecies Glossary |
| Applications | WB, ELISA, Flow, ICC/IF, IHC, IHC |
| Clonality | Polyclonal |
| Host | Goat |
| Conjugate | Unconjugated |
| Concentration | 0.5 mg/ml |
| Immunogen | Synthetic peptide with sequence ESKKDTDEVFSS, representing the C-terminus of the human protein (residues 1423-1434) according to NP_000611. |
| Predicted Species | Canine (100%), Bovine (100%). Backed by our 100% Guarantee. |
| Isotype | IgG |
| Clonality | Polyclonal |
| Host | Goat |
| Gene | NOS1 |
| Purity | Immunogen affinity purified |
| Innovator's Reward | Test in a species/application not listed above to receive a full credit towards a future purchase. |
| Dilutions |
|
||||
| Application Notes | Successful use in ICC/IF has been reported in the literature (PMID: 20140458). It has also been used succesfully in IHC (PMID: 20140458). Use in IHC-Frozen and IHC-whole mount reported in scientific literature (PMID 24728885). Use in Western Blot reported in scientific literature (PMID: 32278831). |
||||
| Theoretical MW | 161 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. |
||||
| Control |
|
||||
| Reviewed Applications |
|
||||
| Publications |
|
| Storage | Store at -20C. Avoid freeze-thaw cycles. |
| Buffer | Tris saline (20 mM Tris pH 7.3, 150 mM NaCl), 0.5% BSA |
| Preservative | 0.02% Sodium Azide |
| Concentration | 0.5 mg/ml |
| Purity | Immunogen affinity purified |
| Images | Ratings | Applications | Species | Date | Details | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
reviewed by:
Verified Customer |
ICC | Mouse | 12/29/2014 |
Summary
|
Secondary Antibodies |
Isotype Controls |
Research Areas for nNOS Antibody (NB100-858)Find related products by research area.
|
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
| Gene Symbol | NOS1 |
| Entrez | |
| Uniprot |
|
![Immunohistochemistry-Paraffin: nNOS Antibody [NB100-858] - Staining of paraffin embedded Human Cortex. Steamed antigen retrieval with citrate buffer pH 6, AP-staining. Antibody at 2.5 ug/mL.](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunohistochemistry-Paraffin-NB100-858-img0006.jpg "Immunohistochemistry-Paraffin: nNOS Antibody [NB100-858] - Staining of paraffin embedded Human Cortex. Steamed antigen retrieval with citrate buffer pH 6, AP-staining. Antibody at 2.5 ug/mL.")
![Flow Cytometry: nNOS Antibody [NB100-858] - Flow cytometric analysis of paraformaldehyde fixed Kelly cells (blue line), permeabilized with 0.5% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (1 ug/mL). IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.](http://images.novusbio.com/fullsize/nNOS-Antibody-Flow-Cytometry-NB100-858-img0003.jpg "Flow Cytometry: nNOS Antibody [NB100-858] - Flow cytometric analysis of paraformaldehyde fixed Kelly cells (blue line), permeabilized with 0.5% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (1 ug/mL). IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.")
![Immunocytochemistry/Immunofluorescence: nNOS Antibody [NB100-858] - Immunofluorescence analysis of paraformaldehyde fixed HeLa cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL), showing membrane, cytoplasmic and nuclear staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL).](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunocytochemistry-Immunofluorescence-NB100-858-img0002.jpg "Immunocytochemistry/Immunofluorescence: nNOS Antibody [NB100-858] - Immunofluorescence analysis of paraformaldehyde fixed HeLa cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL), showing membrane, cytoplasmic and nuclear staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL).")
![Immunocytochemistry/Immunofluorescence: nNOS Antibody [NB100-858] - Wholemount preparations of the myenteric neurons in the distal colon segments following 3 (2a-2d) and 7 (4a-4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 3 (1a-1d) and 7 (3a-3d) days. Myenteric ganglia and neurons labeled with beta-Tubulin Tuj1 (red), nuclei labeled with DAPI (blue) (arrows) can be seen within the ganglion (1b). Smooth muscle cells (asterisks) are also labeled with DAPI (1b). Significant increase in the proportion of nNOS neurons (green) can be seen at both Days 3 and 7 after oxaliplatin treatment. Scale bar = 20 um. Image collected and cropped by CiteAb from the following publication (www.journal.frontiersin.org/article/10.3389/fnins.2013.00030/abstract) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunocytochemistry-Immunofluorescence-NB100-858-img0004.jpg "Immunocytochemistry/Immunofluorescence: nNOS Antibody [NB100-858] - Wholemount preparations of the myenteric neurons in the distal colon segments following 3 (2a-2d) and 7 (4a-4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 3 (1a-1d) and 7 (3a-3d) days. Myenteric ganglia and neurons labeled with beta-Tubulin Tuj1 (red), nuclei labeled with DAPI (blue) (arrows) can be seen within the ganglion (1b). Smooth muscle cells (asterisks) are also labeled with DAPI (1b). Significant increase in the proportion of nNOS neurons (green) can be seen at both Days 3 and 7 after oxaliplatin treatment. Scale bar = 20 um. Image collected and cropped by CiteAb from the following publication (www.journal.frontiersin.org/article/10.3389/fnins.2013.00030/abstract) licensed under a CC-BY license.")
![Immunocytochemistry/ Immunofluorescence: nNOS Antibody [NB100-858] - (A) Wholemount preparations of the myenteric neurons in the distal colon segments following 3 (2a–2d) & 7 (4a–4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 3 (1a–1d) & 7 (3a–3d) days. Myenteric ganglia & neurons labeled with beta -Tubulin Tuj1 (red), nuclei labeled with DAPI (blue) (arrows) can be seen within the ganglion (1b). Smooth muscle cells (asterisks) are also labeled with DAPI (1b). Significant increase in the proportion of NOS neurons (green) can be seen at both Days 3 & 7 after oxaliplatin treatment. Scale bar = 20 μm. (B) Wholemount preparations of the myenteric neurons in the distal colon segments following 14 (2a–2d) & 21 (4a–4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 14 (1a–1d) & 21 (3a–3d) days. The reduction in total number of neurons & increase in the proportion of NOS neurons was found at both Days 14 & 21 after oxaliplatin treatment. Scale bar = 20 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23486839), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-858_goat-polyclonal-nnos-antibody-310202416284925.jpg "Immunocytochemistry/ Immunofluorescence: nNOS Antibody [NB100-858] - (A) Wholemount preparations of the myenteric neurons in the distal colon segments following 3 (2a–2d) & 7 (4a–4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 3 (1a–1d) & 7 (3a–3d) days. Myenteric ganglia & neurons labeled with beta -Tubulin Tuj1 (red), nuclei labeled with DAPI (blue) (arrows) can be seen within the ganglion (1b). Smooth muscle cells (asterisks) are also labeled with DAPI (1b). Significant increase in the proportion of NOS neurons (green) can be seen at both Days 3 & 7 after oxaliplatin treatment. Scale bar = 20 μm. (B) Wholemount preparations of the myenteric neurons in the distal colon segments following 14 (2a–2d) & 21 (4a–4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 14 (1a–1d) & 21 (3a–3d) days. The reduction in total number of neurons & increase in the proportion of NOS neurons was found at both Days 14 & 21 after oxaliplatin treatment. Scale bar = 20 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23486839), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Immunocytochemistry/ Immunofluorescence: nNOS Antibody [NB100-858] - (A) Wholemount preparations of the myenteric neurons in the distal colon segments following 3 (2a–2d) & 7 (4a–4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 3 (1a–1d) & 7 (3a–3d) days. Myenteric ganglia & neurons labeled with beta -Tubulin Tuj1 (red), nuclei labeled with DAPI (blue) (arrows) can be seen within the ganglion (1b). Smooth muscle cells (asterisks) are also labeled with DAPI (1b). Significant increase in the proportion of NOS neurons (green) can be seen at both Days 3 & 7 after oxaliplatin treatment. Scale bar = 20 μm. (B) Wholemount preparations of the myenteric neurons in the distal colon segments following 14 (2a–2d) & 21 (4a–4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 14 (1a–1d) & 21 (3a–3d) days. The reduction in total number of neurons & increase in the proportion of NOS neurons was found at both Days 14 & 21 after oxaliplatin treatment. Scale bar = 20 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23486839), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-858_goat-polyclonal-nnos-antibody-310202416284920.jpg "Immunocytochemistry/ Immunofluorescence: nNOS Antibody [NB100-858] - (A) Wholemount preparations of the myenteric neurons in the distal colon segments following 3 (2a–2d) & 7 (4a–4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 3 (1a–1d) & 7 (3a–3d) days. Myenteric ganglia & neurons labeled with beta -Tubulin Tuj1 (red), nuclei labeled with DAPI (blue) (arrows) can be seen within the ganglion (1b). Smooth muscle cells (asterisks) are also labeled with DAPI (1b). Significant increase in the proportion of NOS neurons (green) can be seen at both Days 3 & 7 after oxaliplatin treatment. Scale bar = 20 μm. (B) Wholemount preparations of the myenteric neurons in the distal colon segments following 14 (2a–2d) & 21 (4a–4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 14 (1a–1d) & 21 (3a–3d) days. The reduction in total number of neurons & increase in the proportion of NOS neurons was found at both Days 14 & 21 after oxaliplatin treatment. Scale bar = 20 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23486839), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![SDS-PAGE TNF-alpha [Unconjugated]](https://images.novusbio.com/images2/TNF-alpha_210-TA_256.jpg)
![Bioactivity TNF-alpha [Unconjugated]](https://images.novusbio.com/images2/TNFalpha_210TA_1658.jpg)
![SEC-MALS TNF-alpha [Unconjugated]](https://images.novusbio.com/images/210-ta_recombinant-human-tnf-alpha-protein-sec-mals-35202312244..jpg)
![Western Blot Catalase Antibody [Unconjugated]](https://images.novusbio.com/images2/Catalase_AF3398_Western_Blot_5287.jpg)
![Simple Western Catalase Antibody [Unconjugated]](https://images.novusbio.com/images2/Catalase_AF3398_Simple_Western_16990.jpg)
![Knockout Validated Catalase Antibody [Unconjugated]](https://images.novusbio.com/images2/Catalase_AF3398_Knockout_Validated_24032.jpg)
![N/A VEGF [HRP]](https://images.novusbio.com/images2/DATA_VEGF_DVE00_ELISA_871.jpg)
![N/A VEGF [HRP]](https://images.novusbio.com/images2/DATA_VEGF_DVE00_ELISA_872.jpg)
![N/A VEGF [HRP]](https://images.novusbio.com/images2/VEGF_DVE00_ELISA_208.jpg)
